Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav - Dolutegravir - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:24 Intel Viiv Integrase inhibitors Organofluorides Pfizer Biology Pharmacology Dolutegravir Shionogi Pharmaceutical industry Pharmaceutical sciences ViiV Healthcare GlaxoSmithKline		Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 94,97 KB Share Document on Facebook

	June 17, 2009 Chemicals Targeting an HIV‐1 Nef/Host Cell Kinase Complex as Novel Anti‐ Retroviral Compounds Damilola A. Adepegba, Department of Natural Sciences, University of Maryland DocID: 1qLnJ - View Document
	GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations DocID: 1aVDG - View Document
	Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav DocID: 1ai1w - View Document
	Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S DocID: 1a5kT - View Document
	Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir in Treatment‐Naïve Adults with HIV‐1  DocID: 1a5bW - View Document